Skip to main content
main-content

14.09.2017 | Original Article – Cancer Research | Ausgabe 12/2017

Journal of Cancer Research and Clinical Oncology 12/2017

Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 12/2017
Autoren:
Nils Winkelmann, Vivien Schäfer, Jenny Rinke, Alexander Kaiser, Philipp Ernst, Sebastian Scholl, Andreas Hochhaus, Thomas Ernst
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00432-017-2518-z) contains supplementary material, which is available to authorized users.

Abstract

Introduction

SETBP1 mutations have been established as a diagnostic marker in myeloid malignancies and are associated with inferior survival. Since there is limited data on their clinical impact and stability during disease progression, we sought to investigate the relationship between SETBP1 mutations and disease evolution.

Methods

Bidirectional Sanger sequencing of the SETBP1 gene was performed for 442 unselected patients with World Health Organization (WHO) defined myeloid disorders. Follow-up analysis was performed on samples from 123/442 patients to investigate SETBP1 mutation dynamics. Targeted deep next-generation sequencing for a panel of 30 leukemia-associated genes was established to study SETBP1 cooperating mutations.

Results

10/442 patients (2.3%) had SETBP1 hotspot mutations (MDS/MPN, n = 7, sAML, n = 3), whereas four patients (1%) had SETBP1 non-hotspot mutations (MPN, n = 1; MDS, n = 2; sAML, n = 1). The median overall survival for patients with SETBP1 hotspot mutations, SETBP1 non-hotspot mutations, and SETBP1 wild type was 14 (range 0–31), 50 (range 0–71), and 47 months (range 0–402), respectively. In Kaplan–Meier analysis, SETBP1 hotspot mutations were significantly associated with reduced overall survival compared to SETBP1 non-hotspot mutations and the SETBP1 wild type (p < 0.001). All 10 patients with SETBP1 hotspot mutations died from relapse or disease progression. Three of four patients with SETBP1 non-hotspot mutations are alive with stable disease. Cooperating CSF3R and TET2 mutations were most frequently observed in patients with SETBP1 hotspot mutations.

Conclusions

Patients with SETBP1 hotspot mutations suffered from aggressive disease with rapid evolution and inferior overall survival. Patients with SETBP1 non-hotspot mutations had less aggressive disease and a more favorable prognosis. Diagnostic screens for SETBP1 hotspot mutations may help identifying this dismal patient group and treat them in multicenter clinical studies.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (DOCX 16 kb)
432_2017_2518_MOESM1_ESM.docx
Supplementary material 2 (DOCX 16 kb)
432_2017_2518_MOESM2_ESM.docx
Supplementary material 3 (DOCX 17 kb)
432_2017_2518_MOESM3_ESM.docx
Supplementary material 4 (XLSX 29 kb)
432_2017_2518_MOESM4_ESM.xlsx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 12/2017

Journal of Cancer Research and Clinical Oncology 12/2017 Zur Ausgabe

Acknowledgement to Reviewers

Reviewer Acknowledgements 2017

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise